ISA Pharmaceuticals Release: Prof. Cornelis Melief to Present Novel AMPLIVANT™ Platform at American Association for Cancer Research Annual Meeting 2013  
4/2/2013 11:10:19 AM

Leiden, The Netherlands, April 2, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT™ platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.

Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“

Symposium: SY27 “New Cancer Vaccines“

Abstract number: SY27-01

Date: April 9, 2013, at 10:40 a.m.

Location: Room 202 at the Washington Convention Center.

The abstract is available at the AACR website

About ISA Pharmaceuticals

ISA Pharmaceuticals B.V. is a biopharmaceutical company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company´s proprietary synthetic long peptide (SLP®) and AMPLIVANT™ platform permits the generation of safe and effective vaccines with a known mechanism of action. SLP® vaccines are broadly applicable to multiple targets and ideally suited as monotherapy or as essential components in combination with conventional cancer treatments.

Two SLP® vaccines are currently in clinical development: ISA101 is targeting human papillomavirus (HPV) induced diseases and ISA102 is targeting p53-overexpressing tumors. Clinical proof-of-concept has been established with ISA101 in Vulvar Intraepithelial Neoplasia (VIN), a pre-cancerous disease caused by HPV.

The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit


ISA Pharmaceuticals B.V.

Gerard Platenburg, Managing Director

J.H. Oortweg 19

2333 CH Leiden

The Netherlands

Tel. +31 71 33 22 310

Media Inquiries:


Dr. Ludger Wess, Ines-Regina Buth

Managing Partner

Tel. +49 40 88 16 59 64, +49 30 23 63 27 68